NCT01974661View on ClinicalTrials.gov

Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

COMBIG-DC (ilixadencel)

Allogenic dendrite-cell based therapeutic vaccine

Trial Locations (1)

SE-413 45

Dept. of Transplantation and Liver Surgery, Sahlgrenska University Hospital, Gothenburg

Sponsors

Lead Sponsor

Mendus
All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Mendus

INDUSTRY

NCT01974661 - Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter